A venture capital firm headquartered in the U.S. invests in pre-seed, seed, and opportunistic Series A tech-bio startups across the country. With access to a strong healthcare and life sciences network, the firm connects portfolio companies with strategic partners and resources to accelerate growth. Initial checks typically range from $300K to $1M, often through syndication or co-investment.
The firm focuses on technology-driven biotechnology companies, particularly those leveraging AI, computational biology, and machine learning to achieve breakthroughs in drug development, diagnostics, precision medicine, and other healthcare innovations. It is indication-agnostic and prioritizes startups where technology forms the core of the value proposition and enables scalable impact.
The firm does not enforce rigid requirements on company structure or team experience, instead seeking strong technical foundations, visionary leadership, and a clear path to commercialization.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment